| Zdroj: |
Auterinen, I, Aschan, C, Benczik, J, Färkkilä, M, Hiismäki, P, Kaita, K, Kallio, M, Kosunen, A, Kulvik, M, Kärkkäinen, M, Ryynänen, P, Savolainen, S, Seppälä, T, Serén, T, Tanner, V, Toivonen, M, Vähätalo, J & Ylä-Mella, H 1997, Current status of the Finnish boron neutron capture therapy (BNCT) project . in E Rauhala & M E Sainio (eds), Proceedings of the XXXI Annual Conference of the Finnish Physical Society : Abstracts ., 12.01/87.00, University of Helsinki, Helsinki, University of Helsinki: Department of Physics. Report Series in Physics, vol. 262, XXXI Annual Conference of the Finnish Physical Society, Helsinki, Finland, 13/03/97 . |
| Popis: |
A research group to carry out clinical application of BNCT was established in Finland in the early 1990's. The neutron irradiations will take place at the Finnish research reactor (FiR 1) operated by VTT in Otaniemi. In April 1996 the new FLUENTALtm neutron moderator developed by VTT was installed and in September a conical beam collimator. Neutron field and dosimetric measurements have confirmed that the epithermal neutron field is suitable for human treatments. In October a thorough renovation of the reactor building has started. The ground and first floor will be converted into a BNCT research and treatment facility. The Monte Carlo based INEL NCT dose planning program rtt_MC has been used in the determination of the brain substitute materials for head phantoms. The program is also used in the healthy tissue tolerance studies. Other efforts in dosimetry include studying the suitability of TL detectors for BNCT. To determine the boron capture dose distribution the boron distribution in the tumour and in the other tissues has to be known in addition to the thermal neutron field. The current efforts on boron bulk-analysis are focused on the methods ICP-AES, PGNA and PIGE. In order to analyse boron distribution at cellular level SIMS will he used combined with freeze-drying and cryosectioning, thus preserving the original boron distribution in the samples. Boron distribution determination in vivo is pursued by radiolabelling boron carriers. Normal tissue tolerance studies in co-operation with CRC Radiobiology Unit, Oxford, England, will contribute towards the verification of the treatment planning, radiation doses, biological effects and radiation safety of BNCT before proceeding to therapies of patients. Boron carrier biodistribution studies of boronophenytalanine (BPA) will be completed in 1998, with data available for the patient treatments. |
